Indian families now pay less for healthcare. Out-of-pocket spending fell from 64.2% to 43.4% in ten years. This is due to the government sp...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Pfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...

Pfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...

Moderna's first-quarter revenue surpassed estimates, driven by strong international COVID-19 vaccine sales. The company forecasts lower-tha...

Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

Markets often climb despite worries. In 2020, markets rose before economic recovery. Now, in 2026, markets are recovering amid geopolitical...

Moderna, the COVID-19 vaccine manufacturer, is poised to meet its 2023 sales target as it taps into the private market. Analysts suggest th...

Covid-19 vaccines' updated versions will be available in the US by mid-September and will be distributed through the commercial market, CDC...

Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting.Adver...

Union Health Minister Mansukh Mandaviya on Tuesday said that the Central Drug Authority CDSCO has approved the Serum Institute of India's C...

The EU Digital COVID certificate or 'Green Pass' will be mandatory to travel to European countries and the document is likely to serve as p...

Three of the vaccines are in the trial phase, two are in the pre-clinical stage, one is in phase 1 and another in phase 2, the Union health...

As per the ministry’s internal timelines, the government expects to approve at least one vaccine by January end.

The World Economic Forum-Ipsos survey of nearly 20,000 adults from 27 countries, unveiled on Monday, showed that 87% urban Indians and 74% ...

Biological E will produce J&J's vaccine at its vaccine production facilities and sell them both in India and export across various global m...